Citations

Clear

4610 citation(s) found for "Lu, Brian".

Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity
Shaffer, Brian C. , Brown, Samantha , Chinapen, Stephanie , Mangold, Kathryn, Lahoud, Oscar , Schaffer, Wendy, Liu, Jennifer E. , Giralt, Sergio , Scordo, Michael , Papadopoulos, Esperanza B. , Landau, Heather , Friedman, Paul A. , Kosmidou, Ioanna , Giralt, Sergio , Papadopoulos, Esperanza , Landau, Heather , Perales, Miguel-Angel , Friedman, Paul A , Attia, Zachi I , Lahoud, Oscar B , López-Jiménez, Francisco , Devlin, Sean M. , Shah, Gunjan L. , Usmani, Saad Z. , Perales, Miguel‐Angel , Gersh, Bernard J. , Attia, Zachi I. , Noseworthy, Peter A.

Mayo Clinic

Blood Advances | August 19, 2024 | Volume: 8 | Issue: 21 | Pages: 5603-5611

10.1182/bloodadvances.2024013636 | PMID 39158065 Get It

Abstract Artificial intelligence (AI)–enabled interpretation of electrocardiogram (ECG) images (AI-ECGs) can identify patterns predictive of future adverse cardiac events. We hypothesized that such an approach would provide prognostic information for the risk of cardiac complications and mortality in patients undergoing hematopoietic cell transplantation (HCT). We retrospectively subjected ECGs obtained before HCT to an externally trained, deep-learning model designed to predict the risk of atrial fibrillation (AF). Included were 1377 patients (849 autologous [auto] HCT and 528 allogeneic [allo] HCT recipients). The median follow-up was 2.9 years. The 3-year cumulative incidence of AF was 9% (95% confidence interval [CI], 7-12) in patients who underwent auto HCT and 13% (10%-16%) in patients who underwent allo HCT. In the entire cohort, pre-HCT AI-ECG estimate of AF risk correlated highly with the development of clinical AF (hazard ratio [HR], 7.37; 95% CI, 3.53-15.4; P < .001), inferior survival (HR, 2.4; 95% CI, 1.3-4.5; P = .004), and greater risk of nonrelapse mortality (NRM; HR, 95% CI, 3.36; 1.39-8.13; P = .007), without increased risk of relapse. Association with mortality was only noted in allo HCT recipients, where the risk of NRM was greater. The use of cyclophosphamide after transplantation resulted in greater 90-day incidence of AF (13% vs 5%; P = .01) compared to calcineurin inhibitor–based graft-versus-host disease prophylaxis, corresponding to temporal changes in AI-ECG AF prediction after HCT. In summary, AI-ECG can inform risk of posttransplant cardiac outcomes and survival in HCT patients and represents a novel strategy for personalized risk assessment.
Loss of HD-PTP function results in lipodystrophy, defective cellular signaling and altered lipid homeostasis
Schultz, Destiny F. , Davies, Brian A., Payne, Johanna A., Martin, Cole P , Minard, Annabel Y. , Childs, Bennett G. , Jeganathan, Karthik B. , Sturmlechner, Ines , White, Thomas A. , Harkema, Liesbeth , Chen, Huiqin , Davies, Michael A. , Jachim, Sarah K. , Hu, Li , Deursen, Jan M. van , Billadeau, Daniel D. , Katzmann, David J. , Jeganathan, Karthik B , Sturmlechner, Ines , de Bruin, Alain , Harkema, Liesbeth , Jachim, Sarah , LeBrasseur, Nathan K , Piper, Robert C , Baker, Darren J , van Deursen, Jan M , Billadeau, Daniel D , Katzmann, David J , Zhang, Cheng , Bruin, Alain de , LeBrasseur, Nathan K. , Piper, Robert C. , Baker, Darren J.

Mayo Clinic

Journal of Cell Science | August 19, 2024 | Volume: 137 | Issue: 18 | Pages: No page available

10.1242/jcs.262032 | PMID 39155850 Get It

ABSTRACT His domain protein tyrosine phosphatase (HD-PTP; also known as PTPN23) facilitates function of the endosomal sorting complexes required for transport (ESCRTs) during multivesicular body (MVB) formation. To uncover its role in physiological homeostasis, embryonic lethality caused by a complete lack of HD-PTP was bypassed through generation of hypomorphic mice expressing reduced protein, resulting in animals that are viable into adulthood. These mice exhibited marked lipodystrophy and decreased receptor-mediated signaling within white adipose tissue (WAT), involving multiple prominent pathways including RAS/MAPK, phosphoinositide 3-kinase (PI3K)/AKT and receptor tyrosine kinases (RTKs), such as EGFR. EGFR signaling was dissected in vitro to assess the nature of defective signaling, revealing decreased trans-autophosphorylation and downstream effector activation, despite normal EGF binding. This corresponds to decreased plasma membrane cholesterol and increased lysosomal cholesterol, likely resulting from defective endosomal maturation necessary for cholesterol trafficking and homeostasis. The ESCRT components Vps4 and Hrs have previously been implicated in cholesterol homeostasis; thus, these findings expand knowledge on which ESCRT subunits are involved in cholesterol homeostasis and highlight a non-canonical role for HD-PTP in signal regulation and adipose tissue homeostasis.
Treatment for chronic idiopathic constipation: Use and satisfaction from a nationwide survey of US participants
Lacy, Brian E. , Xu, Yanqing , Taylor, Douglas C.A., Kosch, Katherine J., Dobrescu, Rachel, Morlock, Amy, Morlock, Robert , Rooker, Ceciel, Rooker, Ceciel

Mayo Clinic

Neurogastroenterology & Motility | August 19, 2024 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/nmo.14885 | PMID 39155456 Get It

AbstractBackgroundChronic idiopathic constipation (CIC) is a disorder of gut–brain interaction characterized by a variety of bowel movement‐related and abdominal symptoms. A greater understanding of medication use and satisfaction with symptom control may provide insights to optimize patient care. Therefore, we explored these aspects of the disorder in adults with CIC.MethodsThis study assessed data collected from a large nationwide survey of adult participants in the United States, querying demographics, clinical characteristics, and comorbid conditions, as well as medication use, care‐seeking behaviors, and satisfaction with symptom control. Participants were grouped into the CIC cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self‐reported.Key ResultsTwo thousand five hundred and thirty‐three participants with CIC were matched 1:1 to controls. In the CIC cohort, abdominal pain was the most reported symptom leading to medication use: 15.9% of respondents were receiving a prescription medication in addition to an over‐the‐counter medication, while 26.3% were taking neither. In addition, only one‐third were satisfied with the control of their symptoms; however, satisfaction was significantly higher in respondents taking a prescription medication (p < 0.001). The proportion of reported comorbidities was significantly higher in the CIC cohort versus the control cohort, with chronic pain, anxiety, and depression among the highest (p < 0.001 for all).Conclusions and InferencesThis study emphasizes the need for better communication regarding prescription medications and their benefits, with the goal of further improving CIC patients' overall symptoms.
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Acharya, Sahaja , Allison, Jenna , Alva, Elizabeth, Arndt, Carola, Benedetti, Daniel J. , Church, Alanna J. , Davidoff, Andrew M. , Desai, Ami V. , DuBois, Steven G. , Fair, Douglas , Farinhas, Joaquim M. , Harrison, Douglas J. , Huang, Frederick S., Iskander, Paul, Kreissman, Susan G. , Macy, Margaret E. , Pashankar, Farzana , Pendyala, Praveen, Polites, Stephanie F. , Rabah, Raja , Shimada, Hiroyuki , Slatnick, Leonora R. , Sokol, Elizabeth , Twist, Clare J. , Vo, Kieuhoa T. , Watt, Tanya , Wolden, Suzanne, Zage, Peter E. , Schonfeld, Ryan, Hang, Lisa, Polites, Stephanie, Bagatell, Rochelle , Park, Julie R. , Aldrink, Jennifer H. , Brown, Erin G. , Cho, Steve K. , Na, Brian , Pinto, Navin

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 16, 2024 | Volume: 22 | Issue: 6 | Pages: 413-433

10.6004/jnccn.2024.0040 | PMID 39151455 Get It

Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of neuroblastoma. The information in these guidelines was developed by the NCCN Neuroblastoma Panel, a multidisciplinary group of representatives with expertise in neuroblastoma, consisting of pediatric oncologists, radiologists, pathologists, surgeons, and radiation oncologists from NCCN Member Institutions. The evidence-based and consensus recommendations contained in the NCCN Guidelines are intended to guide clinicians in selecting the most appropriate treatments for their patients with this clinically heterogeneous disease.
Poster 344: The New "Terrible Triad": Anterior Cruciate Ligament Reconstruction With Concurrent Meniscal Lateral Root and Medial Ramp Repairs
Shoemaker, Evan P , Tollefson, Luke V. , Kennedy, Nicholas I. , Homan, Morgan D. , Shah, Ayush , Sieffert, Kayla J., Wulf, Corey A., Bjerke, Brian, McGaver, Rebecca Stone , Larson, Christopher Michael , LaPrade, Robert F.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 15, 2024 | Volume: 12 | Issue: 7_suppl2 | Pages: No page available

10.1177/2325967124s00310 Get It

Objectives: The purpose of this paper was to compare patient reported outcomes (PROMs) between isolated anterior cruciate ligament (ACLR) and ACLR with concomitant medial meniscus ramp and lateral meniscus root repairs and compare PROMs between different medial meniscus ramp and lateral meniscus root repair techniques. Methods: All patients with isolated (ISO) ACL reconstruction or ACL reconstruction with concomitant medial meniscus ramp and lateral meniscus root repairs with a minimum 2 years of follow-up were retrospectively evaluated. Institutional review board approval was obtained for this study. A final total of 42 ISO-ACL patients were matched based upon age, sex, and body mass index to 40 in the “terrible triad” (TT) cohorts. Outcome measures were obtained from 32 patients in the ISO cohort, and 38 patients in the TT cohort. The PROMs used for this study include the International Knee Documentation Committee (IKDC) Subjective Knee, Cincinnati, Tegner, Lysholm, Veterans RAND 12-Item Health Survey (VR-12), and Knee Injury and Osteoarthritis Outcomes Score (KOOS) questionnaire forms. T tests and chi-square goodness of fit tests were used to compare the above PROMs both pre- and postoperatively within each cohort, and between cohorts and rates of revision or reoperation. Results: The preoperative and postoperative PROMs between patients in the isolated cohort and the triad cohort demonstrated no significant differences, except for the Physical category of the VR-12, in which the triad cohort had significantly higher results (p = 0.04) (Figure 1). Both the isolated cohort and the triad cohort reported significant differences between pre- and postoperative PROMs within their own cohorts. When comparing methods of surgery, including all-inside vs. inside-out for the medial meniscus repairs and tunnel versus no-tunnel for the lateral meniscus root repairs, no significant differences were found between postoperative PROMs. Additionally, no significant difference was found in revision or reoperative rates between the triad and isolated cohorts (p = 0.374) (Figure 2), the all-inside versus inside-out medial meniscus cohorts (p = 0.267), or the tunnel vs. no-tunnel lateral meniscus cohorts (p = 0.781). Conclusions: There was no significant difference in PROMs between isolated ACLR versus ACLR with concomitant medial meniscus ramp and lateral meniscus root repairs. While the complexity of the TT ACLR patients was more involved, PROMs and healing rates were similar and performing concurrent medial ramp and lateral root repairs at the time of ACLR should be considered.
Medicaid Reimbursement for Common Orthopaedic Trauma Procedures Is 16.0% Less Compared With Medicare With Substantial Variability Between States
Moore, M. Lane , Henderson, Adam W, Haglin, Jack M. , Brinkman, Joseph C. , Schuyver, Paul R. Van, Bingham, Joshua S. , Miller, Brian , Adám, H , Moore, M Lane , Henderson, Adam, Van Schuyver, Paul R, Bingham, Joshua S , Adam, Henderson , Schuyver, Paul Van

Mayo Clinic

Journal of Orthopaedic Trauma | August 14, 2024 | Volume: 38 | Issue: 11 | Pages: e362-e370

10.1097/bot.0000000000002901 | PMID 39141357 Get It

OBJECTIVES: This study seeks to evaluate the variability of Medicaid reimbursement and compare it with Medicare reimbursement using the 20 most commonly billed orthopaedic trauma Current Procedural Terminology (CPT) codes nationwide. The authors anticipate significant variability between states and hypothesize that Medicaid payment will be significantly less than Medicare payment. METHODS: The top 20 most common orthopaedic trauma surgery procedural codes were identified from a previous analysis performed by Haglin et al. The Centers for Medicare and Medicaid Services Physician Fee Schedule was used to determine reimbursement rates from Medicare, and state Medicaid fee schedules were used to determine reimbursement rates for Medicaid. State Medicaid rates were compared with their corresponding Medicare rates to determine a dollar difference. In addition, the dollar difference for each CPT code was divided by its respective physician relative value unit. This was used to acknowledge the possible variability in the complexity of orthopaedic procedures and the related physician effort. The Medicare Wage Index was used to adjust Medicaid rates based on the cost of living for the state as well. Coefficients of variation were calculated to represent overall variability in Medicaid and Medicare reimbursement rates. RESULTS: The mean reimbursement rates for Medicaid were lower for all 20 procedures compared with Medicare. On average, Medicaid reimbursed 16.0% less than Medicare and 29.6% less when adjusting for cost of living. MCD reimbursed at a higher rate than MCR for all procedures in only 9 states (Alaska, Arizona, Arkansas, Montana, Nebraska, New Jersey, New Mexico, North Dakota, and South Dakota) while 38 states reimbursed at a lower rate than MCR, on average. The coefficient of variation ranged from 0.24 to 0.34 for the Medicaid unadjusted group and from 0.35 to 0.46 for the Medicare Wage Index–adjusted group. By contrast, the Medicare group was consistent at 0.06 for all 20 procedures. The average dollar difference across the 20 CPT codes for Medicaid reimbursement compared with Medicare reimbursement ranged from −$76.89 to −$225.17, and the dollar difference per relative value unit ranged from −$5.96 to −$15.16. CONCLUSIONS: This study found a high amount of variation between state Medicaid reimbursement rates and average rates that were significantly lower than Medicare reimbursement rates for the top 20 most used orthopaedic trauma CPT codes as identified by Haglin et al. The discrepancy in reimbursement was increased when Medicaid rates were adjusted for state cost of living. LEVEL OF EVIDENCE: Prognostic, Level III. See Instructions for Authors for a complete description of levels of evidence.
Clinical and radiographic outcomes after mechanical thrombectomy in medium-vessel posterior cerebral artery occlusions: Subgroup analysis from STAR
Findlay, Matthew C, Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos , Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Park, Min S. , Levitt, Michael R. , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Matouk, Charles , Altschul, David J , Grandhi, Ramesh , Levitt, Michael R , Crosa, Roberto , Navia, Pedro , Almallouhi, Eyad , Findlay, Matthew C. , Jabbour, Pascal , Rai, Ansaar , Shaban, Amir , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G, Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Leacy, Reade De , Grandhi, Ramesh

Mayo Clinic

Interventional Neuroradiology | August 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241273839 | PMID 39140967 Get It

Background Whereas mechanical thrombectomy (MT) has become standard-of-care treatment for patients with salvageable brain tissue after acute stroke caused by large-vessel occlusions, the results of MT in patients with medium-vessel occlusions (MEVOs), particularly in the posterior cerebral artery (PCA), are not well known. Methods Using data from the international Stroke Thrombectomy and Aneurysm Registry (STAR), we assessed presenting characteristics and clinical outcomes for patients who underwent MT for primary occlusions in the P2 PCA segment. As a subanalysis, we compared the PCA MeVO outcomes with STAR's anterior circulation MeVO outcomes, namely middle cerebral artery (MCA) M2 and M3 segments. Results Of the 9812 patients in STAR, 43 underwent MT for isolated PCA MeVOs. The patients’ median age was 69 years (interquartile range 61–79), and 48.8% were female. The median NIH Stroke Scale score was 9 (range 6–17). After recanalization, 67.4% of patients achieved successful recanalization (modified treatment in cerebral infarction score [mTICI] ≥ 2b), with a first-pass success rate of 44.2%, and 39.6% achieved a modified Rankin score of 0–2 at 90 days. Nine patients (20.9%) had died by the 90-day follow-up. In comparison with M2 and M3 MeVOs, there were no differences in presenting characteristics among the three groups. Patients with PCA MeVOs were less likely to undergo intra-arterial thrombolysis (4.7% PCA vs. 10.1% M2 vs. 16.2% M3, p = 0.046) or to achieve successful recanalization (mTICI ≥ 2b, 67.4%, 86.7%, 82.3%, respectively, p < 0.001); however, there were no differences in the rates of successful first-pass recanalization (44.2%, 49.8%, 52.3%, respectively, p = 0.65). Conclusions We describe the STAR experience performing MT in patients with PCA MeVOs. Our analysis supports that successful first-pass recanalization can be achieved in PCA MEVOs at a rate similar to that in MCA MeVOs, although further study and possible innovation may be necessary to improve successful PCA MeVO recanalization rates.
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs, Jeremy W. , Stanek, C , Symeonidis, Argiris , Shih, Andrew W. , Gavriilaki, Eleni , Pavenski, Katerina , Moorehead, Amy , Mingot‐Castellano, María Eva , Daou, Laetitia , Arnold, Donald M. , Henrie, Ryan , Smith, Tyler , Sreenivasan, Gayatri , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Harrington, Thomas J., Byrnes, Diana M. , Bitsani, Aikaterini , Davis, Amanda K. , Robinson, Danielle H., Eichbaum, Quentin , Kaiafa, Georgia , Klapper, Ellen, Klein, Monica S., Kotsiou, Nikolaos , Lalayanni, Chrysavgi , Mandala, Evdokia , Alkhateb, Rahaf, Fortuny, Lisandro, Mellios, Zois, Papalexandri, Apostolia, Parsons, Meredith G , Wellard, Cameron , Jia, Shiyang , Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bouzid, Raïda , Coppo, Paul, Bloch, Evan M. , Adkins, Brian D. , Stanek, Caroline G , Booth, Garrett , Symeonidis, Argiris , Shih, Andrew W , Gavriilaki, Eleni , Moorehead, Amy , Peyvandi, Flora , Mancini, Ilaria , Raval, Jay S , Mingot-Castellano, Maria Eva , Crowe, Elizabeth P , Arnold, Donald M , Yamada, Chisa , Kotsiou, Nikolaos , Aldarweesh, Fatima , Schlueter, Annette J , Tormey, Christopher A , Wood, Erica M , Wheeler, Allison P , Yates, Sean G , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Parsons, Meredith G , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Pavenski, Katerina , Peyvandi, Flora , Agosti, Pasquale , Stephens, Laura D. , Raval, Jay S. , Pai, Menaka , Marques, Marisa B. , Yamada, Chisa , Robinson, Danielle H. , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Kapsali, Eleni , Perez-Alvarez, Ingrid , Aldarweesh, Fatima , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Coppo, Paul

Mayo Clinic

American Journal of Hematology | August 13, 2024 | Volume: 99 | Issue: 11 | Pages: 2063-2074

10.1002/ajh.27458 | PMID 39136282 Get It

AbstractPrior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5‐year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere—winter (December–February); spring (March–May); summer (June–August); autumn (September–November) and Southern Hemisphere—winter (June–August); spring (September–November); summer (December–February); autumn (March–May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%–31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.
Cochlear Implantation Outcomes in Patients With Sporadic Inner Ear Schwannomas With and Without Simultaneous Tumor Resection
Nassiri, Ashley M. , Staricha, Kelly L. , Neff, Brian A., Driscoll, Colin L. W., Link, Michael J. , Carlson, Matthew L. , Staricha, Kelly

Mayo Clinic

Otology & Neurotology | August 9, 2024 | Volume: 45 | Issue: 9 | Pages: 1051-1054

10.1097/mao.0000000000004268 | PMID 39118256 Get It

Objectives Describe a single institution's cochlear implant outcomes for patients with inner ear schwannomas (IES) in the setting of various tumor management strategies (observation, surgical resection, or stereotactic radiosurgery [SRS]). Study Design Single-institution retrospective review. Patients Patients diagnosed with isolated, sporadic IES who underwent cochlear implantation (CI). Interventions CI with or without IES treatment. Main Outcome Measures Speech perception outcomes, tumor status. Results Twelve patients with IES underwent CI with a median audiologic and radiologic follow-up of 12 months. Six patients underwent complete resection of the tumor at the time of CI, four underwent tumor observation, and two underwent SRS before CI. At 1 year after CI for all patients, the median consonant–nucleus–consonant (CNC) word score was 55% (interquartile range, 44–73%), and the median AzBio sentence in quiet score was 77% (interquartile range, 68–93%). Overall, those with surgical resection performed similarly to those with tumor observation (CNC 58 versus 61%; AzBio in quiet 74 versus 91%, respectively). Patients who underwent tumor resection before implantation had a wider range of speech performance outcomes compared with patients who underwent tumor observation. Two patients had SRS treatment before CI (10 months previous and same-day as CI) with CNC word scores of 6 and 40%, respectively. Conclusions Patients with IES who underwent CI demonstrated similar speech performance outcomes (CNC 56% and AzBio 82%), when compared with the general cochlear implant population. Patients who underwent either tumor observation or surgical resection performed well after CI.
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Hoff, Fieke W. , Blum, William , Huang, Ying , Welkie, Rina Li , Swords, Ronan , Traer, Elie , Stein, Eytan M. , Lin, Tara L. , Patel, Prapti A. , Collins, Robert H. , Baer, Maria R. , Arellano, Martha , Odenike, Olatoyosi , Redner, Robert L. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Foran, James M. , Schiller, Gary J. , Curran, Emily , Koenig, Kristin L , Heerema, Nyla A. , Chen, Timothy L. , Martycz, Molly , Stefanos, Mona , Marcus, Sonja G., Rosenberg, Leonard, Burd, Amy , Yocum, Ashley O. , Borate, Uma , Byrd, John C. , Madanat, Yazan F. , Huang, Ying , Byrd, John C. , Duong, Vu H , Deininger, Michael , Zeidner, Joshua F , Smith, Catherine C , Koenig, Kristin L , Druker, Brian J , Mims, Alice S , Madanat, Yazan , Traer, Elie , Lin, Tara L , Byrd, John C , Archer, Kellie J. , Duong, Vu H. , Stock, Wendy , Zeidner, Joshua F. , Smith, Catherine C. , Marcus, Sonja G., Levine, Ross L.

Mayo Clinic

Blood Advances | August 7, 2024 | Volume: 8 | Issue: 20 | Pages: 5297-5305

10.1182/bloodadvances.2024013685 | PMID 39110987 Get It

Abstract Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ≥60 years treated with lower-intensity treatment (LIT). We aimed to test the prognostic impact of ELN risk in patients with newly diagnosed (ND) AML aged ≥60 years given LIT and to further refine risk stratification for these patients. A total of 595 patients were included: 11% had favorable-, 11% intermediate-, and 78% had adverse-risk AML. ELN risk was prognostic for overall survival (OS) (P &lt; .001) but did not stratify favorable- from intermediate-risk (P = .71). Within adverse-risk AML, the impact of additional molecular abnormalities was further evaluated. Multivariable analysis was performed on a training set (n = 316) and identified IDH2 mutation as an independent favorable prognostic factor, and KRAS, MLL2, and TP53 mutations as unfavorable (P &lt; .05). A “mutation score” was calculated for each combination of these mutations, assigning adverse-risk patients to 2 risk groups: −1 to 0 points (“Beat-AML intermediate”) vs 1+ points (“Beat-AML adverse”). In the final refined risk classification, ELN favorable- and intermediate-risk were combined into a newly defined “Beat-AML favorable-risk” group, in addition to mutation scoring within the ELN adverse-risk group. This approach redefines risk for older patients with ND AML and proposes refined Beat-AML risk groups with improved discrimination for OS (2-year OS, 48% vs 33% vs 11%, respectively; P &lt; .001), providing patients and providers additional information for treatment decision-making.